Education
About Us
Working with TipRanks
Follow Us
Alkermes plc (ALKS)
NASDAQ:ALKS
Earnings Data
Report Date
Apr 29, 2026Before Open (Confirmed)
Period Ending
2026 (Q1)Consensus EPS Forecast
-0.25Last Year’s EPS
0.27Same Quarter Last Year
Strong Buy
Based on 11 Analysts Ratings
Earnings Call Summary
Earnings Call Sentiment|Positive
The call conveyed a largely positive outlook driven by strong 2025 commercial performance (9% growth in proprietary portfolio), solid profitability and cash position, strategic acquisition of Avadel to enter sleep medicine (LUMRIZE), and clear pipeline momentum (elixorexant breakthrough designation and Phase 3 start). Key near‑term headwinds are acquisition accounting effects (inventory step‑up and amortization) producing an expected GAAP loss in 2026, materially higher R&D and SG&A to fund growth and integration, and financing‑related interest expense and debt. Management provided detailed 2026 guidance showing healthy adjusted EBITDA and revenue expansion, while acknowledging payer/competitive risks in the oxybate market and potential VIVITROL dynamics in 2027.Company Guidance
Strong 2025 Revenue and Proprietary Product Growth
Total 2025 revenues nearly $1,500,000,000; proprietary product portfolio net sales ~ $1,200,000,000, up 9% year‑over‑year; proprietary product sales for the year noted as $1,180,000,000.
Key Product Sales Performance
VIVITROL net sales $467,900,000 (≈2% growth YoY); ARISTADA net sales $370,000,000 (≈7% growth YoY); Livaldi net sales $346,700,000 (≈24% growth YoY).
Profitability and Cash Position
2025 GAAP net income $241,700,000; EBITDA $285,600,000; adjusted EBITDA $394,000,000; year‑end cash and investments ~$1,300,000,000.
Acquisition Completed to Expand Commercial Platform
Acquisition of Avadel closed (Feb 2026), adding LUMRIZE and a sleep commercial team; Alkermes used ~$775,000,000 cash and a $1,525,000,000 term loan to fund the deal; expected Loomrise contribution for remainder of 2026 approx. $315,000,000–$335,000,000.
LUMRIZE Commercial Momentum
LUMRIZE 2025 net sales ≈ $279,000,000 with ~3,500 patients on therapy (≈40% increase vs 2024); Alkermes expects full‑year LUMRIZE revenue $350,000,000–$370,000,000 for 2026 and reported ~$33,000,000 in revenue from the first six weeks post‑close.
Ambitious 2026 Financial Guidance
Company expects 2026 total revenues $1,730,000,000–$1,840,000,000 and adjusted EBITDA $370,000,000–$410,000,000; management stated expectation to generate > $1.7B revenue and > $370M adjusted EBITDA for 2026.
Pipeline Progress — Elixorexant Breakthrough and Phase 3
Elixorexant (orexin 2 receptor agonist) granted FDA Breakthrough Therapy designation; plan to initiate global Phase 3 'Brilliance' program in narcolepsy later this quarter (three 12‑week randomized controlled studies; NT1: two ~150‑patient studies; NT2: ~180 patients) with MWT primary endpoint.
Advancement of Additional Orexin Candidates
ALKS 7,290 and ALKS 4,510 progressed through Phase 1 in healthy volunteers with plans to enter patient studies in 2026 (ALKS 7,290 targeting ADHD with Phase 1b and Phase 2 planned; ALKS 4,510 targeting fatigue in MS/Parkinson's with Phase 2a planned).
ALKS Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
ALKS Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
Feb 25, 2026 | $33.39 | $31.04 | -7.04% |
Oct 28, 2025 | $29.72 | $31.00 | +4.31% |
Jul 29, 2025 | $26.15 | $27.00 | +3.25% |
May 01, 2025 | $28.77 | $30.58 | +6.29% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
FAQ
When does Alkermes plc (ALKS) report earnings?
Alkermes plc (ALKS) is schdueled to report earning on Apr 29, 2026, Before Open (Confirmed).
What is Alkermes plc (ALKS) earnings time?
Alkermes plc (ALKS) earnings time is at Apr 29, 2026, Before Open (Confirmed).
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is ALKS EPS forecast?
ALKS EPS forecast for the fiscal quarter 2026 (Q1) is -0.25.